A randomized trial assessing the utility of a test-dose program with taxanes

B. L. Stanford, S. R. Shah, E. E. Ballard, C. A. Jumper, Ian Rabinowitz, J. E. Dowell, W. C. Hunt, J. A. Krieger

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Objective: Taxanes are commonly used anticancer agents with a potential of producing an allergic or hypersensitivity reaction (HSR). We performed a randomized study to evaluate the value of a test dose given prior to the full dose of either paclitaxel or docetaxel. Research design and methods: Patients were randomly assigned to either the administration of the full dose or to the prior administration of a 1 mg intravenous test dose of either paclitaxel or docetaxel. The primary endpoints were severity of the HSR and the cost of drug wastage due to a HSR. Results: Two hundred and eighteen patients were randomized from three different treatment sites. The overall incidence of HSR was 6.5% and there was no significant difference in the incidence of HSR in either group. The mean HSR severity grade was 2.8 for patients without a test dose and 2.3 for those receiving a test dose. There was, however, a reduction in the wastage of taxane in the test dose arm. Wastage avoided in the test dose arm was $1573 per patient who had a HSR and $104 per patient treated with a taxane. Conclusion: Although a test dose may not reduce the severity of a HSR with the administration of a taxane, it does reduce the cost associated with drug wastage.

Original languageEnglish (US)
Article number3130
Pages (from-to)1611-1616
Number of pages6
JournalCurrent Medical Research and Opinion
Issue number10
StatePublished - Oct 2005


  • Docetaxel
  • Hypersensitivity reactions
  • Paclitaxel
  • Taxanes
  • Test dose

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'A randomized trial assessing the utility of a test-dose program with taxanes'. Together they form a unique fingerprint.

Cite this